This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: Next Week's Game Plan

When asked how things are going in China, a country known for its knock-off products, Gelfond said the Chinese love brands, and the Imax brand has yet to be replicated in China. He said the Chinese recognize the quality of the Imax brand and don't seem to want to settle for lesser-quality offerings.

Turning to this season's movie lineup, Cramer asked whether Imax should be considered as a hit-driven business. Gelfond said this is a common misconception; in reality, Imax's revenue per screen has been pretty constant at $1.2 million, no matter how many blockbuster films are expected each year. He said Imax is now playing re-releases including "Titanic" and "The Wizard of Oz" to turnouts as large as for the newest releases.

Cramer said that with consumers tiring of "regular" movies, Imax remains a cut above.

Speculation Friday

For "Speculation Friday," Cramer honed in on Jazz Pharmaceuticals (JAZZ - Get Report) a small biotech stock that has roared recently but may be ready to run even higher.

Cramer said Jazz currently sells for just nine times earnings despite its 16% growth rate. Given an average biotech multiple, he feels the stock could rally another 25% from current levels.

But there's a dark cloud hanging over Jazz, said Cramer, and that's the threat of generic competition. Despite having patents for its key drug, Xyrem, running through 2019, another company is actively developing a competing generic alternative. While Jazz has already sued to stop development, the company risks losing 50% of its revenue if the outcome of that case does not go its way.

Cramer said he's not worried about Jazz' legal woes because he feels the case should be a slam dunk, especially since the company is developing a new formulation of Xyrem that could extend patents even beyond 2019. He said the company's drug pipeline, which includes promising oncology and psychiatric drugs, will make Jazz more than a one-hit wonder by the time its Xyrem patents do finally expire.

Given the stock's big run, Cramer reminded viewers that all of the usual speculative caveats apply -- wait for a pullback, use limit orders and don't pay up for shares.

Lightning Round

In the Lightning Round, Cramer was bullish on American Electric Power (AEP), CVR Refining (CVRR), TransCanada (TRP), Ruth's Chris Steakhouse (RUTH), Darden Restaurants (DRI), Kimberly-Clark (KMB) and Aqua America (WTR).

Cramer was bearish on Southern Company (SO), Clean Harbors (CLH), Hudson City Bancorp (HCBK) and Nuverra Environmental Solutions (NES).

Mad Mail

In the "Mad Mail" viewer feedback segment, Cramer followed up on Chuy's Holdings (CHUY), saying that at 42 times earrings, the stock has become too rich to consider. He was also bearish on Nextera Energy (NEE), saying that the utilities have fallen out of favor and he prefers Duke Energy (DUK) or ConEd (ED).

Cramer was more upbeat on Infinera (INFN), saying that investors could buy some now, but should wait for a pullback to complete their positions. He was also bullish on Waste Management (WM), saying that investors are selling on news that the company may not be allowed to turn itself into a REIT, but he's still buying it for his charitable trust, Action Alerts PLUS .

Cramer was also buying Facebook (FB) for Action Alerts PLUS, even though he admitted that while Facebook is doing great as a company, it's pretty bad as a stock.

Finally, when asked whether he'd bet on Las Vegas Sands (LVS) or the Phillies baseball team, Cramer said he'd go with Las Vegas Sands at this point in the season.

No Huddle Offense

In his "No Huddle Offense" segment, Cramer told viewers that if the market's rally is to continue, we'll need to keep an eye on six macro themes.

First, interest rates need to stabilize after their quick jump upwards. Second, we need to see better data from Europe as well as, third, better data from China. The markets will also need to see stronger retail sales numbers to counter the weaker numbers posted this week.

Finally, Cramer said the markets need to see a rise in commodity prices, which have plummeted on fears of weaker global demand, and the leadership groups like tech and aerospace to return to their leading roles.

Cramer said for the markets to take out their recent highs, all six of these momentum themes need to be heading in the right direction.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
At the time of publication, Cramer's Action Alerts PLUS had positions in FB and WY.

Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for, Inc., and CNBC, and a director and co-founder of All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of or its affiliates, or CNBC, NBC Universal or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or is related to the specific opinions expressed by him on "Mad Money."

None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMAX $32.75 2.30%
JAZZ $152.50 1.20%
AAPL $93.63 -0.12%
FB $118.62 0.88%
GOOG $698.55 0.80%


Chart of I:DJI
DOW 17,888.04 +114.40 0.64%
S&P 500 2,081.59 +16.29 0.79%
NASDAQ 4,818.61 +43.2520 0.91%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs